Scalper1 News
Drugmakers and biotechs have dominated IBD’s 197 industry groups for some time, but leaders in both groups have weakened significantly. IBD’s Medical-Biomedical/Biotech group and the Medical-Ethical Drugs group, both ranked in the top five as of Friday’s IBD, have fallen for two straight weeks while the major averages have risen. There’s been little news to explain the declines, but many stocks in these groups had run up significantly and seemed Scalper1 News
Scalper1 News